Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> GOLDMAN SACHS Latest News

FEB 22, 2013 - Benzinga

A Must Read - Share

UPDATE: Goldman Sachs Downgrades C.R. Bard to Sell on Clinical Trial Risk

Goldman Sachs downgraded C.R. Bard (NYSE: BCR) from Neutral to Sell and lowered the price target from $99.00 to $95.00. Goldman Sachs noted, "With BCR's FY1 P/E multiple having expanded 11.6% vs. an 8% cut to earnings estimates, we think the market is giving Bard too much credit for acceleration in outer-year revenue/EPS growth.

Tags: UPDATE: Goldman Sachs Downgrades C.R. Bard to Sell on Clinical Trial Risk,  Goldman Sachs Latest News